All In Biotech

Drug Trial Radar · NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

952

Planned (sponsor's estimate)

Start

Dec 7, 2022

Primary completion

Dec 2028

Study completion Mar 2029

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Conditions

  • High Grade Epithelial Ovarian Cancer
  • High Grade Serous Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Non-small Cell Lung Cancer
  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
  • Mesothelioma
  • Breast Adenocarcinoma
  • Triple Negative Breast Cancer
  • Hormone Receptor-positive/Her2 Negative Breast Cancer
  • Platinum-resistant Ovarian Cancer (PROC)
  • Platinum Sensitive Ovarian Cancer (PSOC)
  • Primary Refractory Ovarian Cancer
  • Uterine Cancer
  • Cervical Cancer

Interventions

  • Rina-SDrug

    Intravenous infusion of Rina-S

  • CarboplatinDrug

    Carboplatin intravenous infusion

  • BevacizumabDrug

    Bevacizumab intravenous infusion

  • PembrolizumabDrug

    Pembrolizumab intravenous infusion

  • ErythromycinDrug

    Erythromycin oral administration

  • ItraconazoleDrug

    Itraconazole oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]Time frame: Through end of treatment, up to approximately 1 year.
  2. Parts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  3. Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Through end of treatment, up to approximately 1 year.
  4. Part K (US Participants Only) - Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Findings by HolterTime frame: Cycles 1 to 3 (each cycle is 21 days)
  5. Part L - Peak Plasma Concentration (Cmax) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)
  6. Part L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-STime frame: Cycles 1 and 2 (each cycle is 21 days)

Locations

67 sites in 4 countries. Site status is shown where the registry gives one.

  • USOR HonorHealth

    Phoenix, Arizona · Recruiting

  • USOR Arizona Oncology Associates

    Tucson, Arizona · Recruiting

  • University of California Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • University of California, San Diego; Moores Cancer Center

    San Diego, California · Recruiting

  • USOR Sansum Clinic

    Santa Barbara, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • USOR Florida Cancer Specialists South

    Fort Myers, Florida · Recruiting

  • USOR Florida Cancer Specialists North

    St. Petersburg, Florida · Recruiting

  • USOR Florida Cancer Specialists East

    West Palm Beach, Florida · Recruiting

  • Augusta University Georgia Cancer Center

    Augusta, Georgia · Recruiting

  • University of Kansas Medical Center (KUMC)

    Westwood, Kansas · Recruiting

  • USOR Maryland Oncology Hematology

    Rockville, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • USOR Minnesota Oncology Hematology

    Maplewood, Minnesota · Recruiting

  • MD Anderson Cancer Center at Cooper- Two Cooper Plaza

    Camden, New Jersey · Recruiting

  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • University of Oklahoma - Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • USOR Oncology Associates of Oregon, P.C.

    Eugene, Oregon · Recruiting

  • Compass Oncology - Rose Quarter

    Portland, Oregon · Recruiting

  • USOR Alliance Cancer Specialist

    Doylestown, Pennsylvania · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Women and Infants Hospital of Rhode Island

    Providence, Rhode Island · Recruiting

  • Sarah Cannon Research Institute at Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • USOR Texas Oncology

    Abilene, Texas · Recruiting

  • Texas Oncology - Central / South Texas

    Austin, Texas · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • USOR Texas Oncology

    Fort Worth, Texas · Recruiting

  • Texas Oncology - Northeast TX

    Tyler, Texas · Recruiting

  • USOR Texas Oncology Gulf Coast

    Woodland, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • USOR Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • USOR Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Swedish Cancer Institute

    Everett, Washington · Recruiting

  • Cancer hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fujian, China, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangdong, China, China · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.